The degenerating substantia Nigra as a susceptible region for gene transfer-mediated inflammation

Parkinson's Disease

Volumn , Issue , 2011, Pages

  Roca, Valeria ^a   Casabona, Juan Cruz ^a   Radice, Pablo ^a   Murta, Vernica ^a   Pitossi, Fernando Juan ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; IMMUNE MEDIATED INJURY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENE;

EID: 80052712429     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.4061/2011/931572     Document Type: Review

References (74)

1. Hatano T., Kubo S. I., Sato S., Hattori N., Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease Journal of Neurochemistry 2009 111 5 1075 1093
2. Lang A. E., Lozano A. M., Parkinson's disease: second of two parts The New England Journal of Medicine 1998 339 16 1130 1143 (Pubitemid 28465762)
3. Benabid A. L., Gene therapy for Parkinson's disease: do we have the cure? Lancet Neurology 2010 9 12 1142 1143
4. McMenamin M. M., Wood M. J. A., Progress and prospects: immunobiology of gene therapy for neurodegenerative disease: Prospects and risks Gene Therapy 2010 17 4 448 458
5. Lowenstein P. R., Kroeger K., Castro M. G., Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses Neurotherapeutics 2007 4 4 715 724 (Pubitemid 47505348)
6. Kim W. G., Mohney R. P., Wilson B., Jeohn G. H., Liu B., Hong J. S., Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia Journal of Neuroscience 2000 20 16 6309 6316 (Pubitemid 30658427)
7. Castao A., Herrera A. J., Cano J., Machado A., Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system Journal of Neurochemistry 1998 70 4 1584 1592 (Pubitemid 28136972)
8. Godoy M. C. P., Tarelli R., Ferrari C. C., Sarchi M. I., Pitossi F. J., Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease Brain 2008 131 7 1880 1894 (Pubitemid 351957456)
9. Perry V. H., A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation Journal of Neuroimmunology 1998 90 2 113 121
10. Perry V. H., Bell M. D., Brown H. C., Matyszak M. K., Inflammation in the nervous system Current Opinion in Neurobiology 1995 5 5 636 641
11. Lowenstein P. R., Mandel R. J., Xiong W. D., Kroeger K., Castro M. G., Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions Current Gene Therapy 2007 7 5 347 360 (Pubitemid 47595777)
12. Lowenstein P. R., Castro M. G., Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences Gene Therapy 2003 10 11 946 954 (Pubitemid 36722429)
13. Perry V. H., Nicoll J. A. R., Holmes C., Microglia in neurodegenerative disease Nature Reviews Neurology 2010 6 4 193 201
14. Carson M. J., Bilousova T. V., Puntambekar S. S., Melchior B., Doose J. M., Ethell I. M., A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease Neurotherapeutics 2007 4 4 571 579 (Pubitemid 47499284)
15. Colton C. A., Heterogeneity of microglial activation in the innate immune response in the brain Journal of Neuroimmune Pharmacology 2009 4 4 399 418
16. Kreutzberg G. W., Microglia: a sensor for pathological events in the CNS Trends in Neurosciences 1996 19 8 312 318 (Pubitemid 26349059)
17. Glass C. K., Saijo K., Winner B., Marchetto M. C., Gage F. H., Mechanisms underlying inflammation in neurodegeneration Cell 2010 140 6 918 934
18. Long-Smith C. M., Sullivan A. M., Nolan Y. M., The influence of microglia on the pathogenesis of Parkinson's disease Progress in Neurobiology 2009 89 3 277 287
19. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397
20. Ouchi Y., Yagi S., Yokokura M., Sakamoto M., Neuroinflammation in the living brain of Parkinson's disease Parkinsonism and Related Disorders 2009 15 supplement 3 S200 S204
21. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 1988 38 8 1285 1291
22. Tansey M. G., Goldberg M. S., Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention Neurobiology of Disease 2010 37 3 510 518
23. Mirza B., Hadberg H., Thomsen P., Moos T., The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease Neuroscience 1999 95 2 425 432
24. Depino A. M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., Del Rey A., Pitossi F. J., Oertel W. H., Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease European Journal of Neuroscience 2003 18 10 2731 2742 (Pubitemid 37542126)
25. Fadok V. A., Bratton D. L., Konowal A., Freed P. W., Westcott J. Y., Henson P. M., Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF Journal of Clinical Investigation 1998 110 4 890 898 (Pubitemid 28096086)
26. He Y., Lee T., Leong S. K., 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra Brain Research 2000 858 1 163 166 (Pubitemid 30105794)
27. Koprich J. B., Reske-Nielsen C., Mithal P., Isacson O., Neuroinflammation mediated by IL-1 increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease Journal of Neuroinflammation 2008 5, article 8
28. Saura J., Parés M., Bové J., Pezzi S., Alberch J., Marin C., Tolosa E., Mart M. J., Intranigral infusion of interleukin-1 activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity Journal of Neurochemistry 2003 85 3 651 661 (Pubitemid 36531928)
29. Ling Z. D., Gayle D. A., Ma S. Y., Lipton J. W., Tong C. W., Hong J. S., Carvey P. M., In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain Movement Disorders 2002 17 1 116 124 (Pubitemid 36041267)
30. Carvey P. M., Chang Q., Lipton J. W., Ling Z., Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease Frontiers in Bioscience 2003 8 s826 s837
31. He Y., Appel S., Le W., Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum Brain Research 2001 909 1-2 187 193 (Pubitemid 32710132)
32. Hald A., Lotharius J., Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Experimental Neurology 2005 193 2 279 290 (Pubitemid 40616179)
33. Snchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A. L., Isacson O., Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease Journal of Neuroinflammation 2004 1, article 6
34. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H., Przedborski S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease Journal of Neuroscience 2002 22 5 1763 1771 (Pubitemid 35386294)
35. Liu B., Du L., Hong J. S., Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation Journal of Pharmacology and Experimental Therapeutics 2000 293 2 607 617 (Pubitemid 30244114)
36. Castao A., Herrera A. J., Cano J., Machado A., The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF- IL-1 IFN- Journal of Neurochemistry 2002 81 1 150 157 (Pubitemid 34808862)
37. Depino A., Ferrari C., Pott Godoy M. C., Tarelli R., Pitossi F. J., Differential effects of interleukin-1 on neurotoxicity, cytokine induction and glial reaction in specific brain regions Journal of Neuroimmunology 2005 168 1-2 96 110 (Pubitemid 41396407)
38. Pott Godoy M. C., Ferrari C. C., Pitossi F. J., Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression Journal of Neuroimmunology 2010 222 1-2 29 39
39. De Lella Ezcurra A. L., Chertoff M., Ferrari C., Graciarena M., Pitossi F., Chronic expression of low levels of tumor necrosis factor- in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation Neurobiology of Disease 2010 37 3 630 640
40. Ferrari C. C., Pott Godoy M. C., Tarelli R., Chertoff M., Depino A. M., Pitossi F. J., Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1 in the substantia nigra Neurobiology of Disease 2006 24 1 183 193 (Pubitemid 44437611)
41. Tran T. A., McCoy M. K., Sporn M. B., Tansey M. G., The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection Journal of Neuroinflammation 2008 5, article 14
42. McCoy M. K., Martinez T. N., Ruhn K. A., Szymkowski D. E., Smith C. G., Botterman B. R., Tansey K. E., Tansey M. G., Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease Journal of Neuroscience 2006 26 37 9365 9375 (Pubitemid 44396849)
43. McCoy M. K., Ruhn K. A., Martinez T. N., McAlpine F. E., Blesch A., Tansey M. G., Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats Molecular Therapy 2008 16 9 1572 1579
44. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R. B., Brooks D. J., In vivo imaging of microglial activation with [C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiology of Disease 2006 21 2 404 412 (Pubitemid 43099863)
45. Mogi M., Harada M., Kondob T., Riederer P., Inagaki H., Minami M., Nagatsu T., Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor- are elevated in the brain from parkinsonian patients Neuroscience Letters 1994 180 2 147 150
46. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T., Tumor necrosis factor- (TNF- ) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neuroscience Letters 1994 165 1-2 208 210
47. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T., Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication Journal of Neural Transmision 1996 103 8-9 1077 1081 (Pubitemid 26383837)
48. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y., Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathologica 2003 106 6 518 526 (Pubitemid 37441607)
49. Barcia C., Jimenez-Dalmaroni M., Kroeger K. M., Puntel M., Rapaport A. J., Larocque D., King G. D., Johnson S. A., Liu C., Xiong W., Candolfi M., Mondkar S., Ng P., Palmer D., Castro M. G., Lowenstein P. R., One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications Molecular Therapy 2007 15 12 2154 2163 (Pubitemid 350148932)
50. Thomas C. E., Schiedner G., Kochanek S., Castro M. G., Lwenstein P. R., Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases Proceedings of the National Academy of Sciences of the United States of America 2000 97 13 7482 7487 (Pubitemid 30431489)
51. Thomas C. E., Schiedner G., Kochanek S., Castro M. G., Lowenstein P. R., Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors Human Gene Therapy 2001 12 7 839 846 (Pubitemid 32692349)
52. Barcia C., Gerdes C., Xiong W. D., mmunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells Neuron Glia Biology 2006 2 4 309 322
53. Ferrari C. C., Depino A. M., Prada F., Muraro N., Campbell S., Podhajcer O., Perry V. H., Anthony D. C., Pitossi F. J., Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain American Journal of Pathology 2004 165 5 1827 1837 (Pubitemid 39435180)
54. Muruve D. A., Pétrilli V., Zaiss A. K., White L. R., Clark S. A., Ross P. J., Parks R. J., Tschopp J., The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response Nature 2008 452 7183 103 107 (Pubitemid 351355095)
55. Mandel R. J., Rendahl K. G., Spratt S. K., Snyder R. O., Cohen L. K., Leff S. E., Characterization of intrastriatal recombinant adeno-associated virus- mediated gene transfer of human tyrosine hydroxylase and human GTP- cyclohydrolase I in a rat model of Parkinson's disease Journal of Neuroscience 1998 18 11 4271 4284 (Pubitemid 28243820)
56. Peden C. S., Burger C., Muzyczka N., Mandel R. J., Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain Journal of Virology 2004 78 12 6344 6359 (Pubitemid 38715933)
57. Reimsnider S., Manfredsson F. P., Muzyczka N., Mandel R. J., Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat Molecular Therapy 2007 15 8 1504 1511 (Pubitemid 47103062)
58. Mastakov M. Y., Baer K., Symes C. W., Leichtlein C. B., Kotin R. M., During M. J., Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain Journal of Virology 2002 76 16 8446 8454 (Pubitemid 34809096)
59. Eberling J. L., Jagust W. J., Christine C. W., Starr P., Larson P., Bankiewicz K. S., Aminoff M. J., Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 2008 70 21 1980 1983
60. Marks W. J., Ostrem J. L., Verhagen L., Starr P. A., Larson P. S., Bakay R. A., Taylor R., Cahn-Weiner D. A., Stoessl A. J., Olanow C. W., Bartus R. T., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial The Lancet Neurology 2008 7 5 400 408
61. Kaplitt M. G., Feigin A., Tang C., Fitzsimons H. L., Mattis P., Lawlor P. A., Bland R. J., Young D., Strybing K., Eidelberg D., During M. J., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial Lancet 2007 369 9579 2097 2105 (Pubitemid 46935946)
62. Feigin A., Kaplitt M. G., Tang C., Lin T., Mattis P., Dhawan V., During M. J., Eidelberg D., Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease Proceedings of the National Academy of Sciences of the United States of America 2007 104 49 19559 19564
63. Marks W. J. Jr., Bartus R. T., Siffert J., Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial The Lancet Neurology 2010 9 12 1164 1172
64. Jarraya B., Boulet S., Ralph G. S., Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia Science Translational Medicine 2009 1 2 2ra4
65. Pichlmair A., Diebold S. S., Gschmeissner S., Takeuchi Y., Ikeda Y., Collins M. K., Reis E Sousa C., Tubulovesicular structures within Vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via toll-like receptor 9 Journal of Virology 2007 81 2 539 547 (Pubitemid 46067881)
66. Valori C. F., Ning K., Wyles M., Azzouz M., Development and applications of non-HIV-based lentiviral vectors in neurological disorders Current Gene Therapy 2008 8 6 406 418
67. Georgievska B., Kirik D., Bjrklund A., Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system Journal of Neuroscience 2004 24 29 6437 6445 (Pubitemid 38971690)
68. Limberis M. P., Bell C. L., Heath J., Wilson J. M., Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung Molecular Therapy 2010 18 1 143 150
69. Vroemen M., Weidner N., Blesch A., Loss of gene expression in lentivirus- and retrovirus-transduced neural progenitor cells is correlated to migration and differentiation in the adult spinal cord Experimental Neurology 2005 195 1 127 139 (Pubitemid 41121974)
70. Sugama S., Yang L., Cho B. P., DeGiorgio L. A., Lorenzl S., Albers D. S., Beal M. F., Volpe B. T., Joh T. H., Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice Brain Research 2003 964 2 288 294 (Pubitemid 36165153)
71. Chung H. Y., Kim H. J., Kim J. W., Yu B. P., The inflammation hypothesis of aging: molecular modulation by calorie restriction Annals of the New York Academy of Sciences 2001 928 327 335
72. Pelegr C., Canudas A. M., del Valle J., Casadesus G., Smith M. A., Camins A., Palls M., Vilaplana J., Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence Mechanisms of Ageing and Development 2007 128 9 522 528 (Pubitemid 47348068)
73. McMahon E. J., Bailey S. L., Castenada C. V., Waldner H., Miller S. D., Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis Nature Medicine 2005 11 3 335 339 (Pubitemid 40460563)
74. Johnston L. C., Su X., Maguire-Zeiss K., Horovitz K., Ankoudinova I., Guschin D., Hadaczek P., Federoff H. J., Bankiewicz K., Forsayeth J. R., Human interleukin-10 gene transfer is protective in a rat model of parkinson's disease Molecular Therapy 2008 16 8 1392 1399